Breast Cancer Clinical Trial
Official title:
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
The purpose of this study is to determine if hypnotic relaxation therapy is a more effective intervention for improving self-image in women who have been diagnosed with breast or gynecologic cancer when compared to progressive muscle relaxation therapy.
This will be a phase II randomized controlled trial involving two arms: hypnotic relaxation
and progressive muscle relaxation (PMR), using a 2:1 randomization schedule.
1. Evaluate the impact of a hypnotic relaxation intervention compared to progressive muscle
relaxation on body image distress.
Hypothesis 1: Women randomized to the hypnotic relaxation will have significantly more
improvement in body image distress as measured by the Impact of Treatment Scale than
women randomized to receive progressive muscle relaxation at 6 weeks.
2. Evaluate the impact of a hypnotic relaxation intervention compared to progressive
relaxation on sexual self-image, sexual health, and mood.
Hypothesis 2: Women randomized to hypnotic relaxation will show significantly more
improvement on the Sexual Self-Schema Scale, the Patient Reported Outcomes Measurement
Information System (PROMIS) sexual health scale and the Positive-Negative Affect Scale
(PANAS) than women receiving progressive relaxation at 6 weeks.
3. Evaluate the side effects of hypnotic and progressive muscle relaxation. Hypothesis 3a:
Hypnotic relaxation will not be associated with significantly more negative side effects
than progressive muscle relaxation.
Hypothesis 3b: Neither hypnotic nor progressive muscle relaxation will be associated
with negative side effects.
4. Explore the physiologic effects of hypnotic relaxation compared to progressive muscle
relaxation by evaluating cortisol slopes and comparing am/pm cortisol values.
Hypothesis 4a: Women receiving hypnotic relaxation will have a steeper cortisol slope, higher
am and lower pm cortisol concentrations at the end of 6 weeks compared with women receiving
progressive muscle relaxation.
Women will be referred from providers in the Breast and Gynecology Clinics of the University
of Michigan Cancer Center as well as the Symptom Management, Sexual Health and
Psycho-Oncology clinics. The study coordinator will provide education about the trial and a
consent form will be provided for review. If a woman decides to participate, she will sign
the consent form. Sessions will be held at Dr. Barton's behavioral research office located on
Washtenaw Avenue in Ann Arbor, where there is privacy, a recliner, a relaxing environment,
and convenient parking.
Both intervention arms will involve three sessions that will occur at 2 week intervals. Each
visit will last about 40 minutes to an hour.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |